Mechanisms of resistance to decitabine in the myelodysplastic syndrome

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Qin, Taichun ^a   Castoro, Ryan ^a   El Ahdab, Samih ^a   Jelinek, Jaroslav ^a   Wang, Xiaodan ^b   Si, Jiali ^a   Shu, Jingmin ^a   He, Rong ^a   Zhang, Nianxiang ^a   Chung, Woonbok ^a   Kantarjian, Hagop M ^a   Issa, Jean Pierre J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Harbin Institute of Hematology and Oncology   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; DNA; AZACITIDINE; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; CYTOGENETICS; DEOXYCYTIDINE KINASE GENE; DNA METHYLATION; DRUG METABOLISM; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; MUTATOR GENE; MYELODYSPLASTIC SYNDROME; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; REMISSION; CHROMOSOME ABERRATION; DNA SEQUENCE; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; AGED, 80 AND OVER; AZACITIDINE; CHROMOSOME ABERRATIONS; CPG ISLANDS; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; DNA METHYLATION; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 80051718182     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023372     Document Type: Article

References (32)

1. Aul C, Gattermann N, Schneider W, (1992) Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 82: 358-367.
2. Boumber YA, Kondo Y, Chen X, Shen L, Gharibyan V, et al. (2007) RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Res 67: 1997-2005.
3. Hopfer O, Komor M, Koehler IS, Schulze M, Hoelzer D, et al. (2007) DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation. Exp Hematol 35: 712-723.
4. Issa JP, Kantarjian HM, (2009) Targeting DNA methylation. Clin Cancer Res 15: 3938-3946.
5. Plimack ER, Kantarjian HM, Issa JP, (2007) Decitabine and its role in the treatment of hematopoietic malignancies. Leuk Lymphoma 48: 1472-1481.
6. Galmarini CM, Mackey JR, Dumontet C, (2001) Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15: 875-890.
7. Stam RW, den Boer ML, Meijerink JP, Ebus ME, Peters GJ, et al. (2003) Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 101: 1270-1276.
8. Qin T, Jelinek J, Si J, Shu J, Issa JP, (2009) Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. Blood 113: 659-667.
9. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, et al. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079-2088.
10. Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, et al. (2008) Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 113: 1351-1361.
11. Clark SJ, Harrison J, Paul CL, Frommer M, (1994) High sensitivity mapping of methylated cytosines. Nucleic Acids Res 22: 2990-2997.
12. Kroeger H, Jelinek J, Estecio MR, He R, Kondo K, et al. (2008) Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 112: 1366-1373.
13. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R, (2003) Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 35: 146-150.
14. Estecio MR, Yan PS, Ibrahim AE, Tellez CS, Shen L, et al. (2007) High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res 17: 1529-1536.
15. Maegawa S, Hinkal G, Kim HS, Shen L, Zhang L, et al. (2010) Widespread and tissue specific age-related DNA methylation changes in mice. Genome Res 20: 332-340.
16. Herman JG, Jen J, Merlo A, Baylin SB, (1996) Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 56: 722-727.
17. Roman-Gomez J, Castillejo JA, Jimenez A, Cervantes F, Boque C, et al. (2003) Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa. J Clin Oncol 21: 1472-1479.
18. Liu ZJ, Zhang XB, Zhang Y, Yang X, (2004) Progesterone receptor gene inactivation and CpG island hypermethylation in human leukemia cancer cells. FEBS Lett 567: 327-332.
19. Wong KY, So CC, Loong F, Chung LP, Lam WW, et al. (2011) Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS ONE 6: e19027.
20. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, et al. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20: 2429-2440.
21. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, et al. (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10: 223-232.
22. Chabot GG, Bouchard J, Momparler RL, (1983) Kinetics of deamination of 5-aza-2′-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside. Biochem Pharmacol 32: 1327-1328.
23. Momparler RL, (2005) Pharmacology of 5-Aza-2′-deoxycytidine (decitabine). Semin Hematol 42: S9-16.
24. Kroep JR, Loves WJ, van der Wilt CL, Alvarez E, Talianidis I, et al. (2002) Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 1: 371-376.
25. Owens JK, Shewach DS, Ullman B, Mitchell BS, (1992) Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res 52: 2389-2393.
26. Al-Madhoun AS, van der Wilt CL, Loves WJ, Padron JM, Eriksson S, et al. (2004) Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2′-2′-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000. Biochem Pharmacol 68: 601-609.
27. Veuger MJ, Honders MW, Spoelder HE, Willemze R, Barge RM, (2003) Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines. Leuk Res 27: 445-453.
28. Stegmann AP, Honders MW, Kester MG, Landegent JE, Willemze R, (1993) Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2′-deoxycytidine. Leukemia 7: 1005-1011.
29. Kobayashi T, Kakihara T, Uchiyama M, Fukuda T, Kishi K, et al. (1994) Low expression of the deoxycytidine kinase (dCK) gene in a 1-beta-D-arabinofuranosylcytosine-resistant human leukemic cell line KY-Ra. Leuk Lymphoma 15: 503-505.
30. van den Heuvel-Eibrink MM, Wiemer EA, Kuijpers M, Pieters R, Sonneveld P, (2001) Absence of mutations in the deoxycytidine kinase (dCK) gene in patients with relapsed and/or refractory acute myeloid leukemia (AML). Leukemia 15: 855-856.
31. Flasshove M, Strumberg D, Ayscue L, Mitchell BS, Tirier C, et al. (1994) Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia 8: 780-785.
32. Konopleva M, Andreeff M, (2007) Targeting the leukemia microenvironment. Curr Drug Targets 8: 685-701.